Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
ablate, angioedema, antitumor, ascending, biomarker, cavity, cetuximab, chronic, CIU, concept, degranulation, differentiation, dimerization, disrupting, effector, Emerging, fever, footage, footprint, gene, half, HNSSC, hypoxia, idiopathic, IgE, inactivating, IND, inflammatory, inhibitory, itchy, KIT, lab, leukotriene, MA, mast, meaningful, Needham, NJ, notable, NOTCH, Omalizumab, onset, outlined, play, relief, robust, role, roughly, save, SCF, sequencing, sizeable, somatic, suppression, symptomatic, uPR, urticaria, variant
Removed:
lesion, METRIC, prioritized, rapidly
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view